Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Share-based Compensation: 2014-2024

Historic Share-based Compensation for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $42.1 million.

  • Viridian Therapeutics, Inc.\DE's Share-based Compensation rose 29.01% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.3 million, marking a year-over-year decrease of 30.28%. This contributed to the annual value of $42.1 million for FY2024, which is 37.25% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Share-based Compensation of $42.1 million as of FY2024, which was down 37.25% from $67.2 million recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Share-based Compensation peaked at $67.2 million during FY2023, and registered a low of $6.0 million during FY2020.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Share-based Compensation averaged around $43.0 million, with its median value being $42.1 million (2024).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Share-based Compensation soared by 239.85% in 2023, and later tumbled by 37.25% in 2024.
  • Viridian Therapeutics, Inc.\DE's Share-based Compensation (Yearly) stood at $6.0 million in 2020, then skyrocketed by 141.08% to $14.5 million in 2021, then skyrocketed by 36.64% to $19.8 million in 2022, then skyrocketed by 239.85% to $67.2 million in 2023, then plummeted by 37.25% to $42.1 million in 2024.